MoonLake Immunotherapeutics (MLTX) has provided an update.
MoonLake Immunotherapeutics has announced the backing of both the FDA and EMA for advancing their Phase 3 program for Nanobody® sonelokimab in treating psoriatic arthritis, signaling a major step forward. This approval sets the stage for the IZAR trial, aiming to enroll 1,500 patients to substantiate a future biologics license. While the news is promising, it’s important to note that these forward-looking statements are subject to various uncertainties, underscoring the inherent risks of drug development and the volatility that can accompany such announcements in the financial markets.
Learn more about MLTX stock on TipRanks’ Stock Analysis page.
